

Chapter 135

Xanthomatoses and Lipoprotein Disorders

Ernst J. Schaefer & Raul D. Santos

REFERENCES

1. Expert Panel: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) *J Am Med Assoc* **285**:2486-2497, 2001
2. Grundy SM et al: Implications of recent clinical trials for the national cholesterol education adult treatment Panel III guidelines. *Circulation* **110**:227-239, 2004
3. Schaefer EJ: E.V. McCollum Award Lecture: Lipoproteins, nutrition, and heart disease. *Am J Clin Nutr* **75**:191-212, 2002
4. Sprecher DS et al: Cardiovascular features of homozygous familial hypercholesterolemia: Analysis of 16 patients. *Am J Cardiol* **54**:20-30, 1984
5. Sprecher DL et al: The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia. *Metabolism* **34**:294-299, 1985.
6. Hobbs HH, Brown MJ, Goldstein JL: Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. *Human Mutat* **1**:445-466, 1992
7. Civeira F et al; Spanish Familial Hypercholesterolemia Group: Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. *Arterioscler Thromb Vasc Biol* **25**(9):1960-1965, 2005
8. Holven KB et al: Patients with familial hypercholesterolaemia show enhanced spontaneous chemokine release from peripheral blood mononuclear cells ex vivo. Dependency of xanthomas/xanthelasms, smoking and gender. *Eur Heart J* **24**(19):1756-1762, 2003
9. Matsuura F et al: Familial massive tendon xanthomatosis with decreased high-density lipoprotein-mediated cholesterol efflux. *Metabolism* **54**(8):1095-1101, 2005
10. Pauciuolo P et al: Increased carotid artery intima-media thickness is associated with a novel mutation of low-density lipoprotein receptor independently of major cardiovascular risk factors. *Metabolism* **52**(11):1433-1438, 2003
11. Neil HA et al: Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: A prospective registry study. *Atherosclerosis* **170**(1):73-78, 2003
12. Harada-Shiba M et al: Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. *J Clin Endocrinol Metab* **88**(6):2541-2547, 2003
13. Hopkins PN: Familial hypercholesterolemia—Improving treatment and meeting guidelines. *Int J Cardiol* **89**(1):13-23, 2003
14. Cohen JC et al: Molecular mechanisms of autosomal recessive hypercholesterolemia. *Curr Opin Lipidol* **14**(2):121-127, 2003
15. Harada-Shiba M et al: Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. *J Clin Endocrinol Metab* **88**(6):2541-2547, 2003
16. Hopkins PN: Familial hypercholesterolemia—Improving treatment and meeting guidelines. *Int J Cardiol* **89**(1):13-23, 2003
17. Dedoussis GV: Apolipoprotein polymorphisms and familial hypercholesterolemia. *Pharmacogenomics* **8**(9):1179-1189, 2007
18. Sibley C, Stone NJ: Familial hypercholesterolemia: A challenge of diagnosis and therapy. *Cleve Clin J Med* **73**(1):57-64, 2006
19. Oosterveer DM et al: Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: A systematic review and meta-analysis. *Atherosclerosis* **207**(2):311-317, 2009
20. Farese RV Jr, Linton MF, Young SG: Apolipoprotein B mutations affecting cholesterol levels. *J Intern Med* **231**:643-652, 1992
21. Patel MD, Thompson PD: Phytosterols and vascular disease. *Atherosclerosis* **186**:12-19, 2006
22. Kidambi S, Patel SB: Sitosterolemia, pathophysiology, clinical presentation, and laboratory diagnosis. *J Clin Pathol* **61**(5):588-594, 2008

23. Mymin D et al: Image in cardiovascular medicine. Aortic xanthomatosis with coronary ostial occlusion in a child homozygous for a nonsense mutation in ABCG8. *Circulation* **107**(5):791, 2003
24. Matthan NB et al: Alterations in cholesterol absorption and synthesis characterize framingham offspring study participants with coronary disease. *J Lipid Res* **50**:1927-1935, 2009
25. Keren Z, Falik-Zaczel TC: Cerebrotendinous xanthomatosis (CTX), a treatable lipid storage disorder. *Pediatr Endocrinol Rev* **7**:6-11, 2009
26. Sundaram SS et al: Mechanisms of disease: Inborn errors of bile acid synthesis. *Nat Clin Pract Gastroenterol Hepatol* **5**(8):456-468, 2008
27. Kinoshita M et al: Enhanced susceptibility of LDL to oxidative modification in a CTX patient: role of chenodeoxycholic acid in xanthoma formation. *J Atheroscler Thromb* **11**(3):167-172, 2004
28. Lamon-Fava S et al: Two novel mutations in the sterol 27-hydroxylase gene causing cerebrotendinous xanthomatosis. *Clin Genet* **61**:185-191, 2002
29. van Himbergen TM et al: Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. *J Lipid Res* **50**:730-739, 2009
30. Altmann SW et al: Niemann-Pick C1 Like 1 protein is critical for intestinal absorption. *Science* **303**:1201-1204, 2004
31. Davis HR Jr et al: Cholesterol homeostasis by the intestine: Lessons from Niemann Pick C1 Like 1 (NPC1L1). *Atheroscler Suppl* **9**:77-81, 2008
32. Sudhop T et al: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. *Circulation* **106**:1943-1948, 2002
33. Pearson TA et al: Pooled analysis of effects on C reactive protein and low density lipoprotein cholesterol in placebo controlled trials of ezetimibe or ezetimibe added to baseline statin therapy. *Am J Cardiol* **103**:369-374, 2009
34. Schaefer EJ et al: Lipoprotein(a) levels predict coronary heart disease in the lipid research clinics coronary prevention trial. *JAMA* **271**:999-1003, 1994
35. Emerging Risk Factors Collaboration; Erqou S et al: Lipoprotein(a) as a risk factor coronary heart disease and stroke. *JAMA* **302**:412-423, 2009
36. Genest JJ et al: Prevalence of familial lipoprotein disorders in patients with premature coronary artery disease. *Circulation* **85**:2025-2033, 1992.
37. Jenner JL et al: The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a) in human beings. *Metabolism* **54**:361-369, 2005
38. Kashyap ML et al: Long-term safety and efficacy of a once daily niacin/lovastatin formulation. *Am J Cardiol* **893**:672-678, 2002
39. van Himbergen T et al: Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway. *Arterioscler Thromb Vasc Biol* **30**:1113-1120, 2010
40. Ghosh YK, Pradhan E, Ahluwalia HS: Excision of xanthelasmata—Clamp, shave, and suture. *Int J Dermatol* **48**(2):181-183, 2009
41. Brom DJ et al: Dysbetalipoproteinemia: Clinical and pathophysiologic features. *S Afr Med J* **92**:892-897, 2002
42. Schaefer EJ et al: Familial apolipoprotein E deficiency. *J Clin Invest* **78**:1206-1219, 1986
43. Connelly PW, Hegele RA: Hepatic lipase deficiency. *Crit Rev Clin Lab Sci* **35**:547-572, 1998
44. Deeb SS et al: Hepatic lipase and dyslipidemia: Interactions among genetic variants, obesity, and diet. *J Lipid Res* **44**:1279-1286, 2003
45. Schaefer EJ et al: Plasma apolipoprotein A-I absence associated with marked reduction of high density lipoproteins and premature coronary artery disease. *Arteriosclerosis* **2**:16-26, 1982
46. Ordovas JM et al: Familial apolipoprotein A-I, C-III, and A-IV deficiency with marked high density lipoprotein deficiency and premature atherosclerosis due to a deletion of the apolipoprotein A-I, C-III, and A-IV gene complex. *J Biol Chem* **264**:16339-16342, 1989
47. Norum RA et al: Familial deficiency of apolipoproteins A-I and C-III and precocious coronary artery disease. *N Engl J Med* **306**:1513-1519, 1982
48. Karathanasis SK, Ferris E, Haddad EA: DNA inversion within the apolipoprotein AI/CIII/AIV-encoding gene cluster of certain patients with premature atherosclerosis. *Proc Natl Acad Sci* **84**:7198-7202, 1987
49. Ng DS et al: Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein deficiency in a family with analphalipoproteinemia. *J Clin Invest* **93**:223-229, 1994
50. Santos RD et al: Characterization of high density lipoprotein particles in familial apolipoprotein A-I deficiency with premature coronary atherosclerosis, corneal arcus and opacification, and tubo-eruptive and planar xanthomas. *J Lipid Res* **49**:349-357, 2008
51. Santos RD et al: Clinical presentation, laboratory values, and coronary heart disease risk in marked high density lipoprotein deficiency states. *J Clin Lipidol* **2**:237-247, 2008

52. Ikewaki K et al: A novel two nucleotide deletion in apolipoprotein A-I gene, apoA-I Shinbashi, associated with high density lipoprotein deficiency, corneal opacities, planar xanthomas, and premature coronary artery disease. *Atherosclerosis* **172**:39-45, 2004
53. Stockman A et al: Diffuse plane normolipemic xanthomatosis in a patient with chronic lymphatic leukaemia and monoclonal gammopathy. *Dermatology* **204**(4):351-354, 2002
54. Misselwitz B et al: Hyperlipidemic myeloma: Review of 53 cases. *Ann Hematol* **89**(6):569-577, 2010
55. Decaux O et al: Systemic manifestations of monoclonal gammopathy. *Eur J Intern Med* **20**(5):457-461, 2009
56. Burnside NJ et al: Type III hyperlipoproteinemia with xanthomas and multiple myeloma. *J Am Acad Dermatol* **53**(5 Suppl 1):S281-S284, 2005
57. Rahalkar AR et al: Novel LPL mutations associated with lipoprotein lipase deficiency: Two case reports and a literature review. *Can J Physiol Pharmacol* **87**(3):151-160, 2009
58. Shinozaki S et al: Diabetic lipemia with eruptive xanthomatosis in a lean young female with apolipoprotein E4/4. *Diabetes Res Clin Pract* **70**(2):183-192, 2005
59. Baigent C et al: Cholesterol Treatment Trialists Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* **366**:1267-1278, 2005
60. Ridker PM et al: JUPITER Trial Study Group. Reduction in C reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial. *Lancet* **373**:1175-1182, 2009
61. Lamon-Fava S et al: Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. *J Lipid Res* **48**:1746-1753, 2007
62. Staels B et al: Mechanisms of action of fibrates on lipid and lipoprotein metabolism. *Circulation* **98**:2088-2093, 1998
63. Watts GF et al: Differential effects of atorvastatin and fenofibrate on lipoprotein kinetics in subjects with the metabolic syndrome. *Diabetes* **52**:803-811, 2003
64. Manninen V et al: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. *J Am Med Assoc* **260**:641-651, 1988
65. Robins SJ et al: for the VA-HIT Study Group: Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: A randomized controlled trial. *J Am Med Assoc* **285**:1585-1591, 2001
66. The DAIS Investigators: Effect of fenofibrate on the progression of coronary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study (DAIS): a randomized trial. *Lancet* **357**:1890-1895, 2001
67. Keech AC et al; FIELD Investigators: Effects of long term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): a randomized controlled trial. *Lancet* **366**:1849-1861, 2005
68. Keech AC et al; FIELD Study Investigators: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy. (FIELD Study): A randomized controlled trial. *Lancet* **370**:1687-1697, 2007
69. Rajamani K et al: Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): A prespecified analysis of a randomised controlled trial. *Lancet* **373**:1780-1788, 2009
70. Canner PL et al: Fifteen year mortality in Coronary Drug Project patients: Long term benefits with niacin. *J Am Coll Cardiol* **8**:1245-1255, 1986
71. Berge KG, Canner PL: Coronary drug project: Experience with niacin. Coronary Drug Project Research Group. *Eur J Clin Pharm* **40**(Suppl 1):S49-S51, 1991
72. Canner PL et al: Benefits of niacin by glycemic status in patients with healed myocardial infarction. From the Coronary Drug Project. *Am J Cardiol* **95**:254-257, 2005
73. Canner PL, Furberg CD, McGovern ME: Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction; from the Coronary Drug project. *Am J Cardiol* **97**:477-479, 2006
74. Brown GB et al: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary artery disease. *N Engl J Med* **345**:1583-1592, 2001.
75. Asztalos BF et al: Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. *Arterioscler Thromb Vasc Biol* **23**:847-852, 2003
76. Lamon-Fava S et al: Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apoB-containing lipoproteins. *Arterioscler Thromb Vasc Biol* **28**:1672-1678, 2008

77. The Lipid Clinics Coronary Primary Prevention Trial results: II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. *J Am Med Assoc* **251**:365-374, 1984.
78. Fonseca VA et al: Colesevelam HCL improves glycemic control and lowers LDL-C in patients with inadequate control of type II diabetes on sulfonylurea therapy. *Diabetes Care* **31**:1479-1484, 2008
79. Phillipson BE et al: Reduction of plasma lipids, lipoproteins, and apolipoproteins by dietary fish oils in patients with hypertriglyceridemia. *N Engl J Med* **312**:1210-1216, 1985
80. Endres S et al: Dietary n-3 polyunsaturated fatty acids suppress synthesis of interleukin-1 and tumor necrosis factor. *N Eng J Med* **320**:265-271, 1989
81. Davidson MH et al: Combination prescription omega 3 fatty acids with simvastatin (COMBOS). *Clin Ther* **29**:1354-1367, 2007
82. Chan DC et al: Randomized controlled trial of the effects of n3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral adiposity. *Am J Clin Nutr* **77**:300-307, 2003
83. Burr ML et al: Effects of changes in fat, fish, and fibre intakes on death and myocardial infarction. *Lancet* **2**:757-761, 1989
84. Burr ML: Secondary prevention of coronary heart disease in UK men: The Diet and Reinfarction Trial and its sequel. *Proc Nutr Soc* **66**:9-15, 2007
85. Gissi Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the Gissi Prevenzione Trial. *Lancet* **354**:447-455, 1999
86. Yokoyama M et al; for the Japan EPA lipid intervention study (JELIS) investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolemic patients (JELIS): A randomized open label, blinded endpoint analysis. *Lancet* **370**:1090-1098, 2007
87. Tanaka K et al: JELIS Investigators Japan. Reduction in the recurrence of stroke by EPA for hypercholesterolemic patients: Subanalysis of the JELIS trial. *Stroke* **39**:2052-2058, 2008
88. Saito Y et al: JELIS Investigators Japan. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). *Atherosclerosis* **200**:135-140, 2008
89. Brouwer IA et al: Effect of fish oil on ventricular tachyarrhythmias in 3 studies in patients with implantable cardioverter defibrillators. *Eur Heart J* **30**:820-826, 2009
90. Schaefer EJ et al: Plasma phosphatidylcholine docosahexaenoic acid content, and risk of dementia and Alzheimer's disease: The Framingham Study. *Arch Neurol* **63**:1545-1550, 2006